PLEASE COPY AND CIRCULATE WITHIN YOUR FACILITY

Pfizer Australia Pty Ltd
ABN: 50 008 422 348
Level 15, 151 Clarence Street
Sydney, NSW, 2000

25th June 2024

Dear Healthcare Professional,

TEMPORARY ALTERNATIVE SUPPLY ARRANGEMENT UNDER SECTION 14/14A OF THE *Therapeutic Goods Act 1989* FOR:
DBL AMIKACIN 500mg/2mL (as sulfate) injection vial (ARTG 49945)

There is currently a supply interruption of the following presentation listed below.

Presentation	Pack Size	Pfizer Item Code	Estimated Back in Stock Date
DBL AMIKACIN 500mg/2mL (as sulfate) injection vial (ARTG 49945)	5 x 2mL	F000040573	31/12/2024

The supply interruption is due to a manufacturing capacity constraint for **DBL AMIKACIN 500mg/2mL (as sulfate) injection vial (49945).** There are no safety concerns with the above product.

To cover this supply interruption period, Pfizer will supply Amikacin 500mg/2mL approved for use in the United Kingdom (UK).

Presentation	Pack Size	Pfizer Item Code
DBL AMIKACIN 500mg/2mL (as sulfate) injection vial UK (ARTG 49945)	5 x 2mL	**F000039764**

This product is identical in formulation and quality aspects to the Australian product. However, there are some differences, such as the appearance of packaging and the information contained in the leaflet packed with the product. There will be labels overstickered on the packaging to provide important information. Please discard the UK Product Information leaflet contained in the pack and refer to the DBL AMIKACIN 500mg/2mL (as sulfate) injection vial Australian Product Information available at https://www.tga.gov.au/ for Australian-approved indications, dosage and administration.

Please direct all medical enquiries regarding DBL AMIKACIN injection to Pfizer Medical Information on: 1800 675 229 from 9am-5pm AEDT, Mon-Fri or via www.pfizermedicalinformation.com.au for assistance

Should you have any enquiries on stock availability, please contact Pfizer Customer Service on: 1800 629 921.

Adverse Event Reporting

Reporting of suspected adverse events is important for the monitoring of the safety of all medicines. Any adverse events which are experienced with these products should be reported by healthcare professionals and/or patients to the TGA via http://www.tga.gov.au/reporting-problems or to Pfizer on 1800 675 229 or by email to AUS.AEReporting@pfizer.com.

Yours sincerely,

Yuen Lai
Hospital & Community Medicine Medical Lead
Pfizer Australia and New Zealand